|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
GlaxoSmithKline (GSK) Pays $90 Million to Settle States' Avandia Claims
11/16/2012 7:36:41 AM
GlaxoSmithKline P.L.C. agreed to pay $90 million to settle claims by 37 states, including Pennsylvania and New Jersey, and the District of Columbia that the company illegally promoted the Avandia diabetes medicine. The settlement resolves claims by state attorneys general that the London-based Glaxo misled consumers about whether Avandia caused heart attacks and strokes in order to pump up sales. The company has paid more than $3 billion to resolve government probes of its marketing of Avandia and other medications, as well as patient lawsuits over the diabetes drug. "This settlement, which is covered by existing provisions, marks an important step in resolving long-standing legal matters," Bernadette King, a spokeswoman for the company, said in a statement. Glaxo has large operations in the Philadelphia area. The settlements are part of Glaxo's push to resolve legal issues stretching back more than a decade. Company officials agreed in July to plead guilty to misdemeanor criminal charges and pay $3 billion to settle U.S. criminal and civil investigations into whether it illegally marketed Avandia and other medications. One of the criminal charges stemmed from the company's failure to properly report clinical safety data about Avandia, according to court filings. The company also agreed to pay more than $700 million to settle patients' claims that Avandia caused heart attacks and strokes, people familiar with the accords said last year.
|
|
|
|
|
|
|
|
|
|
|